These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)]. Popova NF Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):110-3. PubMed ID: 21916166 [No Abstract] [Full Text] [Related]
3. New drugs may improve, complicate treatment for multiple sclerosis. Link H; Martin R Nat Med; 2010 Mar; 16(3):272. PubMed ID: 20208513 [No Abstract] [Full Text] [Related]
4. Fingolimod for multiple sclerosis. Pelletier D; Hafler DA N Engl J Med; 2012 Jan; 366(4):339-47. PubMed ID: 22276823 [No Abstract] [Full Text] [Related]
5. Fingolimod and multiple sclerosis: four cautionary tales. Bourdette D; Gilden D Neurology; 2012 Nov; 79(19):1942-3. PubMed ID: 23035058 [No Abstract] [Full Text] [Related]
6. Trial watch: Phase III promise for oral multiple sclerosis therapy. Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180099 [No Abstract] [Full Text] [Related]
8. Lethal arrhythmia due to fingolimod, a S1P receptor modulator: are we overestimating or underestimating? Mori M J Neurol Neurosurg Psychiatry; 2015 Aug; 86(8):823. PubMed ID: 25855398 [No Abstract] [Full Text] [Related]
9. [New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod]. Komoly S Ideggyogy Sz; 2012 Nov; 65(11-12):421-2. PubMed ID: 23289178 [No Abstract] [Full Text] [Related]
10. Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod. Tully T; Barkley A; Silber E Neurology; 2015 May; 84(19):1999-2001. PubMed ID: 25878178 [No Abstract] [Full Text] [Related]
11. [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis]. Klatt J; Hartung HP; Hohlfeld R Nervenarzt; 2007 Oct; 78(10):1200-8. PubMed ID: 17668161 [TBL] [Abstract][Full Text] [Related]
13. Oral fingolimod to treat multiple sclerosis: see your cardiologist first. Sato DK; Callegaro D Arq Neuropsiquiatr; 2014 Sep; 72(9):651-2. PubMed ID: 25252227 [No Abstract] [Full Text] [Related]
14. [Disease modifying drugs in multiple sclerosis and pregnancy]. Tur C; Tintoré M; Aguilera C Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277 [No Abstract] [Full Text] [Related]
15. Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism. Voon V; Saiva L; O'Kelly S; Keane D Eur J Clin Pharmacol; 2014 Mar; 70(3):373-5. PubMed ID: 24309839 [No Abstract] [Full Text] [Related]
16. The pill times 2: what every woman with multiple sclerosis should know. Langer-Gould AM Neurology; 2014 Feb; 82(8):654-5. PubMed ID: 24463629 [No Abstract] [Full Text] [Related]
17. [New disease-modifying and symptomatic therapies for multiple sclerosis]. Weise G; Buttmann M MMW Fortschr Med; 2012 Apr; 154(7):64-6. PubMed ID: 22558878 [No Abstract] [Full Text] [Related]
18. [Fingolimod treatment in multiple sclerosis]. Tanaka M Nihon Rinsho; 2014 Nov; 72(11):2010-4. PubMed ID: 25518386 [TBL] [Abstract][Full Text] [Related]
19. Fingolimod-associated amenorrhea: a report of three cases. Alroughani R Mult Scler; 2014 Oct; 20(12):1662-4. PubMed ID: 24515730 [TBL] [Abstract][Full Text] [Related]
20. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis. Ward MD; Jones DE; Goldman MD Expert Opin Drug Saf; 2014 Jul; 13(7):989-98. PubMed ID: 24935480 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]